Federated Hermes Inc. buy 846 shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Federated Hermes Inc. increased its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 1.5% in the second quarter, HoldingsChannel.com reports. The firm owned 56,807 shares of the company’s stock after acquiring an additional 846 shares during the period. Holdings of Federated Hermes Inc. in Myriad Genetics were worth $1,389,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Hexagon Capital Partners LLC grew its position in shares of Myriad Genetics by 75.3% in the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company’s stock worth $28,000 after buying an additional 491 shares during the last quarter. Inçalta Capital LLC purchased a new stake in Myriad Genetics in the second quarter valued at approximately $36,000. Neo Ivy Capital Management acquired a new position in Myriad Genetics in the second quarter valued at $85,000. Quest Partners LLC grew its position in shares of Myriad Genetics by 10,724.5% during the second quarter. Quest Partners LLC now owns 5,304 shares of the company’s stock worth $130,000 after purchasing an additional 5,255 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Myriad Genetics in the second quarter valued at $162,000. 99.02% of shares are held by hedge funds and other institutional investors.

Countless genetics price performance

NASDAQ:MYGN opened at $27.64 on Friday. The company’s fifty day moving average is $27.47 and its two hundred day moving average is $24.07. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -9.80 and a beta of 1.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.78, and a current ratio of 1.96. Myriad Genetics, Inc. has a one year low of $13.82 and a one year high of $29.30.

Myriad Genetics (NASDAQ:MYGN – Get Free Report ) last posted its earnings results on Tuesday, August 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $211.50 million for the quarter, compared to the consensus estimate of $206.44 million. Myriad Genetics had a negative return on equity of 5.64% and a negative net margin of 19.35%. The company’s revenue was up 15.3% compared to the same quarter last year. In the same quarter last year, the company earned ($0.21) earnings per share. Research analysts expect that Myriad Genetics, Inc. to record -0.34 EPS for the current year.

Analysts set new price targets

MYGN has been the subject of several research analyst reports. Morgan Stanley started coverage on Myriad Genetics in a research note on Thursday. They set an “equal weight” rating and a $32.00 target price on the stock. TD Cowen boosted their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group restated an “underperform” rating and issued a $20.00 price objective (down from $25.00) on shares of Myriad Genetics in a research report on Monday, June 3rd. Piper Sandler upped their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 13th. Finally, Scotiabank upped their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the stock a “sector outperform” rating in a report on Tuesday, August 13th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. Myriad Genetics presently has a consensus rating of “Hold” and a consensus price target of $28.91, based on data from MarketBeat.com.

View the latest stock analysis on a multitude of genetics

Insider Trading at Myriad Genetics

In related news, Director Heinrich Dreismann sold 10,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $27.05, for a total value of $270,500.00. Following the completion of the transaction, the director now directly owns 121,648 shares in the company, valued at approximately $3,290,578.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC’s website. In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of Myriad Genetics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $27.05, for a total value of $270,500.00. Following the completion of the transaction, the director now owns 121,648 shares of the company’s stock, valued at $3,290,578.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this link. Also, Director Colleen F. Reitan sold 46,012 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the sale, the director now directly owns 42,533 shares in the company, valued at $1,188,797.35. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s shares.

Countless genetic profiles

(Free Report)

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, women’s and pharmacogenomics. It also offers the MyRisk Hereditary Cancer Test, a DNA sequencing test for risk assessment for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected germline BRCA variants; and the MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in ovarian cancer patients.

Further reading

Want to see what other hedge funds own MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report).

Get news and reviews for Myriad Genetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Myriad Genetics and related companies with MarketBeat.com’s FREE daily email newsletter.